PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial

• Published in: Science bulletin Vol. 69; no. 4; pp. 535 - 543
• Main Authors: Maggie Liu, Si-Yang, Huang, Jie, Deng, Jia-Yi, Xu, Chong-Rui, Yan, Hong-Hong, Yang, Ming-Yi, Li, Yang-Si, Ke, E-E, Zheng, Ming-Ying, Wang, Zhen, Lin, Jia-Xin, Gan, Bin, Zhang, Xu-Chao, Chen, Hua-Jun, Wang, Bin-Chao, Tu, Hai-Yan, Yang, Jin-Ji, Zhong, Wen-Zhao, Li, Yangqiu, Zhou, Qing, Wu, Yi-Long
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 26.02.2024
• Subjects: Antibodies, Monoclonal, Humanized; B7-H1 Antigen - metabolism; Carcinoma, Non-Small-Cell Lung - drug therapy; Humans; Lung Neoplasms - drug therapy; Non-small cell lung cancer; PD-1 inhibitor; PD-L1 expression; Pembrolizumab; Prospective Studies; Sintilimab; PD-L1 expression; Sintilimab; Pembrolizumab; PD-1 inhibitor; Non-small cell lung cancer
• ISSN: 2095-9273; 2095-9281
• DOI: 10.1016/j.scib.2023.12.046

[Display omitted] No direct comparison has been performed between different programmed cell death-1 (PD-1) inhibitors for first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The feasibility of using PD-L1-expression-guided immunotherapy remains unknown. In this open-label, phase 2 study (NCT04252365), patients with advanced NSCLC without EGFR or ALK alterations were randomized (1:1) to receive sintilimab or pembrolizumab monotherapy (PD-L1 expression ≥ 50%), or sintilimab or pembrolizumab plus platinum-based chemotherapy (PD-L1 expression < 50%). The sample size was calculated by optimal two-stage design. The primary endpoint was the objective response rate (ORR). The study included 71 patients (sintilimab arms, n = 35; pembrolizumab arms, n = 36) and met its primary endpoint, with a confirmed ORR of 51.4% (18/35) in the sintilimab arms. The confirmed ORR (95% confidence interval) was 46.2% (19.2%, 74.9%) and 42.9% (17.7%, 71.1%) for patients treated with sintilimab and pembrolizumab monotherapy; and 54.5% (32.2%, 75.6%) and 45.4% (24.4%, 67.8%) for those treated with sintilimab- and pembrolizumab-based combination therapies. The median progression-free survival was 6.9 versus 8.1 months for all sintilimab-treated versus all pembrolizumab-treated patients, respectively, in which it was 7.6 versus 11.0 months in monotherapy and 7.4 versus 7.1 months in combination therapies. The median overall survival was 14.9 versus 21.3 months for all sintilimab-treated versus all pembrolizumab-treated patients, respectively, in which it was 14.9 versus 22.6 months in monotherapy and 14.7 versus 17.3 months in combination therapies. Treatment-related adverse events were consistent with safety outcomes of monotherapy and combination therapy in previous phase III studies. However, the incidence of rash was higher with sintilimab than pembrolizumab monotherapy. This is the first prospective phase 2 study to directly compare two anti-PD-1 antibodies as first-line treatment in advanced NSCLC. Sintilimab was efficacious and well-tolerated irrespective of PD-L1 expression level in patients with advanced NSCLC and had similar efficacy and safety to pembrolizumab.